Skip to main content
. 1999 Apr 13;96(8):4325–4329. doi: 10.1073/pnas.96.8.4325

Figure 4.

Figure 4

Preferential killing of transformed cells by peptidic cyclin/cdk2 antagonists. (A) The indicated cell lines were treated with the Tat-LDL peptide. Cell viability was measured by using an MTS assay. (B) WI38 and WI38/VA13 cells were treated with the indicated peptides, and cell viability was measured by MTS assay. (C). Phase-contrast (Left) and fluorescence microscopy (Right) of WI38/VA13 (Upper) and WI38 cells (Lower) treated with fluorescein-labeled Tat-LDL peptide.